Upajak (Upadacitinib) is a generic version of RINVOQ which is a selective Janus kinase (JAK) inhibitor used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and ankylosing spondylitis. By specifically targeting JAK1, it helps regulate immune responses and reduce inflammation more effectively than traditional treatments.
